Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)

Author:

Beutler Bryce D.1,Shinozuka Kenneth23ORCID,Tabaac Burton J.45,Arenas Alejandro6,Cherian Kirsten7,Evans Viviana D.8,Fasano Chelsey9,Muir Owen S.1011

Affiliation:

1. University of Southern California, Keck School of Medicine, Los Angeles, CA;

2. Centre for Eudaimonia and Human Flourishing, University of Oxford, Oxford, United Kingdom;

3. Department of Psychiatry, University of Oxford, Oxford, United Kingdom;

4. University of Nevada, Reno School of Medicine, Reno, NV;

5. Department of Neurology, Carson Tahoe Health, Carson City, NV;

6. Department of Anesthesiology, University of Washington School of Medicine, Seattle, WA;

7. Department of Psychiatry & Behavioral Sciences, Stanford University, Palo Alto, CA;

8. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY;

9. Teachers College, Columbia University, New York, NY;

10. Fermata Health, Brooklyn, NY; and

11. Acacia Clinics, Sunnyvale, CA

Abstract

Background: Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20th century, it was used to augment psychoanalysis and to treat alcohol use disorder. However, LSD was banned in 1970 in part because of concerns that it could bring about or exacerbate mental illness. Its therapeutic potential remains incompletely understood. Areas of Uncertainty: While uncontrolled recreational use of LSD can, in rare instances, lead to long-term psychosis, adverse events in clinical trials of LSD, such as anxiety, headache, and nausea, have almost always been mild and transient. Serious adverse events, such as intense panic, suicidal ideation, and psychosis, were reported in either none or very few of the participants. However, patient selection criteria, optimal dosing strategy, and appropriate clinical follow-up guidelines remain to be established. Therapeutic Advances: Preliminary data suggest that LSD may be effective for the management of alcohol use disorder, anxiety, and depression. In trials of LSD for treating anxiety and depression associated with life-threatening illnesses, 77% of participants demonstrate durable relief at 1 year post-treatment. Top-line data from a large-scale phase IIb trial (n = 198) indicate that 50% of participants experience remission from generalized anxiety disorder after a single 100 μg dose of LSD. According to a meta-analysis of RCTs on LSD from the mid-20th century, single-dose regimens of LSD significantly improve alcohol use disorder (P < 0.0003) with an odds ratio (OR) of 1.96. Limitations: Only one large-scale clinical trial (>50 participants) has been conducted on LSD in the contemporary era of psychedelic research. Further studies with large sample sizes are needed to explore potential clinical applications. Conclusions: Preliminary data suggest that LSD may be one of the most potent treatments for anxiety in patients both with and without a life-threatening illness. LSD may also be beneficial for treating depression and substance use disorders.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3